...
首页> 外文期刊>Journal of Medicinal Chemistry >Identification of Novel Medulloblastoma Cell-Targeting Peptides for Use in Selective Chemotherapy Drug Delivery
【24h】

Identification of Novel Medulloblastoma Cell-Targeting Peptides for Use in Selective Chemotherapy Drug Delivery

机译:新型Medulloblastoma细胞靶向肽用于选择性化疗药物递送的细胞靶向肽

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Medulloblastoma is a malignant brain tumor diagnosed in children. Chemotherapy has improved survival rates to approximately 70%; however, children are often left with long-term treatment side effects. New therapies that maintain a high cure rate while reducing off-target toxicity are required. We describe for the first time the use of a bacteriophage-peptide display library to identify heptapeptides that bind to medulloblastoma cells. Two heptapeptides that demonstrated high [E1-3 (1)] or low [E1-7 (2)] medulloblastoma cell binding affinity were synthesized. The potential of the peptides to deliver a therapeutic drug to medulloblastoma cells with specificity was investigated by conjugating E1-3 (1) or E1-7 (2) to doxorubicin (5). Both peptide-drug conjugates were cytotoxic to medulloblastoma cells. E1-3 doxorubicin (3) could permeabilize an in vitro blood-brain barrier and showed a marked reduction in cytotoxicity compared to free doxorubicin (5) in nontumor cells. This study provides proof-of-concept for developing peptide-drug conjugates to inhibit medulloblastoma cell growth while minimizing offtarget toxicity.
机译:Medulloblastoma是诊断为儿童的恶性脑肿瘤。化疗提高了80%的生存率;然而,儿童往往留下长期治疗副作用。需要进行高固化率的新疗法,同时减少偏离靶向毒性。我们首次描述使用噬菌体肽显示文库来鉴定与MedullophaStoma细胞结合的七肽。合成了展示高[E1-3(1)]或低[E1-7(2)] Medulloblastoma细胞结合亲和力的两种七肽。通过将E1-3(1)或E1-7(2)与多柔比星(5)缀合出具有特异性的肽以特异性递送治疗药物的肽的潜力。肽 - 药物缀合物均为细胞毒性对medulloblastoma细胞。 E1-3多柔比星(3)可以透露体外血脑屏障,并且与非传出细胞中的游离多柔比星(5)相比,细胞毒性的显着降低。该研究提供了培养肽 - 药物缀合物的概念证据,以抑制Medulloblastoma细胞生长,同时最小化开发毒性。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2020年第5期|共13页
  • 作者单位

    UNSW Sydney ARC Ctr Excellence Convergent Bionano Sci &

    Techn Australian Ctr Nanomed Sydney NSW 2052 Australia;

    UNSW Sydney Childrens Canc Inst Lowy Canc Res Ctr Tumour Biol &

    Targeting Program Sydney NSW 2031 Australia;

    UNSW Sydney Childrens Canc Inst Lowy Canc Res Ctr Tumour Biol &

    Targeting Program Sydney NSW 2031 Australia;

    UNSW Sydney ARC Ctr Excellence Convergent Bionano Sci &

    Techn Australian Ctr Nanomed Sydney NSW 2052 Australia;

    UNSW Sydney Pancreat Canc Translat Res Grp Lowy Canc Res Ctr Sydney NSW 2052 Australia;

    UNSW Sydney ARC Ctr Excellence Convergent Bionano Sci &

    Techn Australian Ctr Nanomed Sydney NSW 2052 Australia;

    UNSW Sydney Childrens Canc Inst Lowy Canc Res Ctr Tumour Biol &

    Targeting Program Sydney NSW 2031 Australia;

    UNSW Sydney Childrens Canc Inst Lowy Canc Res Ctr Tumour Biol &

    Targeting Program Sydney NSW 2031 Australia;

    UNSW Sydney Childrens Canc Inst Lowy Canc Res Ctr Tumour Biol &

    Targeting Program Sydney NSW 2031 Australia;

    UNSW Sydney Childrens Canc Inst Lowy Canc Res Ctr Tumour Biol &

    Targeting Program Sydney NSW 2031 Australia;

    UNSW Sydney ARC Ctr Excellence Convergent Bionano Sci &

    Techn Australian Ctr Nanomed Sydney NSW 2052 Australia;

    UNSW Sydney Childrens Canc Inst Lowy Canc Res Ctr Tumour Biol &

    Targeting Program Sydney NSW 2031 Australia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号